Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 Therapeutics > Exam 1 - Random Info > Flashcards

Exam 1 - Random Info Flashcards

1
Q

6-MP polymorphism

A

TPMT loss of function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

cytarabine synergy agent

a. leucovorin
b. tetrahydrouridine
c. dexrazoxane
d. 5-FU

A

b. tetrahydrouridine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

cisplatin toxicity

A

nephrotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

irinotecan polymorphism

a. TPMT
b. UGT1A1
c. BRAF-V600
d. T315l

A

b. UGT1A1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

drug given with doxorubicin to protect against anthracycline-induced cardiotoxicity

A

dexrazoxane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

bleomycin main toxicity

A

pulmonary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

which has a lower rate of neurotoxicity?

a. vincristine
b. eribulin

A

b. eribulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

formulation for GnRH analogs for breast cancer (i.e. leuprolide)

A

depot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

which drug does not result in “flare” of testosterone production?

a. leuprolide
b. goserelin
c. triptorelin
d. degarelix

A

d. degarelix

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

common SE of abiraterone

A

inc cholesterol levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what drug inhibits the function of 17 alpha-hydroxylase and C17,20 lyase?

a. abiraterone
b. fulvestrant
c. exemestane
d. alectinib

A

a. abiraterone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

drug that can inhibit the “gatekeeper” T315l mutation

a. alectinib
b. quizartinib
c. ponatinib
d. dabrafenib

A

c. ponatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

drug that is specific for internal tandem duplication (ITD) mutations

a. sirolimus
b. alectinib
c. quizartinib
d. trametinib

A

c. quizartinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which drug inhibits immune response by blocking IL-2 signaling transduction?

a. sirolimus
b. dabrafenib
c. trametinib
d. afatinib

A

a. sirolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

which drug is a type III allosteric kinase inhibitor?

a. gefitinib
b. alectinib
c. trametinib
d. acalabrutinib

A

c. trametinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what drug is used in combo with trametinib for BRAFV600E mutant metastatic melanoma?

A

dabrafenib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

kinase inhibitor that is effective for T790M mutation

a. trametinib
b. lapatinib
c. tucatinib
d. osimertinib

A

d. osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

drug that is EGFR and HER2 reversible inhibitor

A

lapatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

which antibody is it mentioned that there is ~3% severe infusion reaction?

A

cetuximab

20
Q

antibody that targets VEGF

A

bevacizumab

21
Q

antibody that targets VEGF receptor

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

A

b. ramucirumab

22
Q

antibody that binds CD20 only to inhibit B-cell proliferation

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

A

d. rituximab

23
Q

antibody that targets CD38, a protein highly expressed on plasma B cells that make antibodies

a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab

A

c. daratumumab

24
Q

antibody that targets CTLA-4 receptor and has a severe inflammatory response

a. ipilimumab
b. ramucirumab
c. daratumumab
d. rituximab

A

a. ipilimumab

25
Q

antibody that binds PD-1 receptor expressed on T-cells

a. atezolizumab
b. pembrolizumab
c. trastuzumab emtansine
d. teclistamab

A

b. pembrolizumab

26
Q

antibody that binds PD-L1 receptor expressed on macrophages and tumor cells

a. atezolizumab
b. pembrolizumab
c. trastuzumab emtansine
d. teclistamab

A

a. atezolizumab

27
Q

mouse, chimeric, humanized, and fully human

A

mouse = o
chimeric = xi
humanized = zu
fully human = u

28
Q

two antibody-drug conjugates to know

A

-trastuzumab emtansine
-trastuzumab deruxtecan

29
Q

trastuzumab emtansine: what is emtansine’s role?

A

inhibits microtubule assembly

30
Q

SE of emtansine (2 of them)

A

thrombocytopenia, hepatotoxicity

31
Q

which BiTE binds to CD3 and brings activated T-cell into proximity of CD19?

a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab

A

a. blinatumomab

32
Q

which BiTE targets CD3 and CD20?

a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab

A

b. mosunetuzumab

33
Q

which BiTE targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma cells?

a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab

A

c. teclistamab

34
Q

which BiTE targets CD3 on T cells and human G-protein coupled receptor family C group 5 member D (GPRC5D) on multiple myeloma cells?

a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab

A

d. taquetamab

35
Q

which class of drugs causes cytokine release syndrome?

A

BiTE’s

36
Q

PD-1 is expressed on which of the following? SELECT ALL THAT APPLY

a. T-cells
b. macrophages
c. tumor cells

A

a. T-cells

37
Q

PD-L1 is expressed on which of the following? SELECT ALL THAT APPLY

a. T-cells
b. macrophages
c. tumor cells

A

b. macrophages
c. tumor cells

38
Q

goal of Sipulcel-T (Provenge)

A

to stimulate a pt’s own immune system to attack the cancer

39
Q

which agent is a PAP-GM-CSF?

A

Sipulcel-T (Provenge)

40
Q

target for CAR-T therapies from class

A

CD19

41
Q

Sipulcel-T can cause flu-like symptoms and a possible inc risk of ______

A

stroke

42
Q

The antibody Fakeumab has just entered the market. What type of the antibody was it?

a. Fully human
b. Humanized
c. Fully mouse
d. Chimeric

A

a. Fully human

43
Q

Which antibody is effective against metastatic melanoma and targets CTLA-4?

a. Ipilimumab
b. Trastuzumab
c. Daratumumab
d. Blinatumomab

A

a. Ipilimumab

44
Q

Which of the following proteins is used as a cancer biomarker test to determine eligibility for treatment of NSCLC with pemrolizumab?

a. CD19
b. CTLA4
c. PDL1
d. PD1

A

c. PDL1

45
Q

Which of the following antigens is a common target for CAR-T therapy in B cell malignancy?

A) CD4
B) CD19
C) CD28
D) CTLA4

A

B) CD19

46
Q

What is the primary mechanism of action of bispecific T cell engagers in cancer immunotherapy?

A) They inhibit the PD1/PDL1 interaction

B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity

C) They stimulate the innate immune system to recognize tumor cells.

D) They increase neoantigens.

A

B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity

PHRM 864 Therapeutics (28 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions